Skip to main content
logo
Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.8525
-0.0459 (-5.11%)
Oct 30, 2026, 10:26 AM EDT - Market open

Coherus Oncology Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
50.9442.1726.39257.24211.04326.55
Revenue Growth
61.00%59.81%-89.74%21.89%-35.37%-31.37%
Gross Profit
35.1228.3617.6698.25140.96268.96
Operating Income
-154-176.43-189.05-193.2-256.88-263.86
Net Income
-132.13168.0228.51-237.89-291.75-287.1
Earnings Per Share
-1.001.430.25-2.53-3.76-3.81
EPS Growth
-476.38%----

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
105.31172.13125.99117.75191.68417.2
Total Debt
54.1854.36298.65480.84480.42419.02
Net Cash (Debt)
51.13117.76-172.66-363.09-288.74-1.83
Net Cash Growth
-72.14%-----
Net Cash Per Share
0.391.01-1.51-3.86-3.72-0.02

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-186.03-138.51-20.44-174.88-241.12-37.43
Capital Expenditures
------1.29
Free Cash Flow
-186.03-138.51-20.44-174.88-241.12-38.72
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
68.95%67.24%66.93%38.19%66.79%82.36%
Operating Margin
-302.33%-418.37%-716.41%-75.10%-121.72%-80.80%
Pretax Margin
-316.37%-434.23%-816.23%-92.62%-138.24%-87.92%
Profit Margin
-259.41%398.43%108.03%-92.48%-138.25%-87.92%
FCF Margin
-365.23%-328.45%-77.46%-67.98%-114.25%-11.86%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-1.025.58---
Forward PE
-138.2923.3123.3123.3123.31
PS Ratio
2.734.076.031.443.683.75